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influence the outcome of treatment. The objective was to assess patient preferences 
on treatments for ED by applying Conjoint Analysis. Methods: Seven attributes 
were selected through a literature review and a consultation with 25 patients treated 
of ED and 5 experts: effectiveness (E), rapidity of onset (R), duration of effect (D), 
adverse events (AE), methods of administration (MA), price (P) and interaction with 
alcohol and food (I). 3 groups of scenarios were selected using “Orthogonal Design”: 
Phase 1, 9 scenarios with 4 attributes (R, D, MA, I); Phase 2, 16 scenarios with the 7 
attributes; Phase 3, 9 scenarios with 4 attributes (E, MA, P, I). It was applied the “Order 
of simulated preference” method by using cards with symbols and text. Interactions 
of age, comorbidity and frequency of sexual intercourses with preferences were 
studied. Results: The set of 16 scenarios was very difficult for patients. A total 
of 314 patients participated in Phase 1, 99 in Phase 2 and 178 in Phase 3. Order of 
preferred attributes: Phase 1: MA (57.99%), D (16.68%), I (14.57%) y R (10.76%); Phase 
2: MA (40.53%),E (21.98%), R (8.98%), P (8.11%), D (7.46%), AE (6.67%),I (6.25%); Phase 
3: MA (53.9%), I (22.45%), P (12.50%), E (11.14%). The preferred MA in the 3 phases 
was the orodispersible tablet with reference to pill and injectable. No statistically 
significant associations were found with age, comorbidity and frequency of sex-
ual intercourse. ConClusions: . Patients gave more importance to the attribute 
“method of administration” in any of the three phases performed. The preferred 
MA was orodispersible tablet over pill and injectable.
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objeCtives: The EQ-5D-3L descriptive classification defines a total of 243 health 
states which presents a problem when seeking to establish social preferences. As 
it would be challenging to value all 243 health states, a subset is chosen but the 
basis for this selection varies across national valuation studies. The aim of this 
study was to choose health states based on the most commonly found health states 
experienced by the Irish population. Methods: EQ-5D data from four different 
datasets were combined to determine what health states are prevalent in Ireland. 
Data from a general population study of health (SLAN), an over 70 population cohort, 
a rheumatoid arthritis and psoriatic arthritis cohort. The most commonly experi-
enced health states were determined and these were arranged on a 5 dimensional 
lattice. Health states were chosen using the Manhattan distance metric. Results: 
A total of 12,520 ratings of self-reported EQ-5D health states were included. Fifty 
two per cent of the cohort had perfect health (11111). Ninety five per cent of states 
include at least one ‘1’ and no ‘3’. 126/243 health states were not experienced in 
these datasets. The Manhattan distance between health states was measured. The 
imposition of such a metric facilitated the identification of clusters of states and 
associated centroids. Distance sampling was used to identify states within the clus-
ters. A simple random sampling strategy was also used across the lattice to ensure 
coverage of health states outside of the cluster ConClusions: Previous population 
preference elicitation studies have used theoretical approaches to health states 
elicitation, which could lead to health states being directly valued which are rarely 
experienced in the population. The approach presented here uses the information 
already known about the population, to inform choice of health states for population 
valuation of health using the EQ-5D.
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objeCtives: To describe HUI reference statistics available from clinical and general 
population health studies. Methods: Reviews of published literature, unpublished 
reports and corporate databases were used to identify summary statistics or data 
available for calculation of summary statistics. Published examples illustrate the use 
of HUI reference statistics for health-related quality of life (HRQL) scores to assess the 
health of patients relative to general populations and of general populations between 
countries. Results: Summary statistics of HRQL scores were compiled from pub-
lished clinical studies (n= 5), population health surveys (n= 6), or provided by investiga-
tors of individual studies (n= 3). Statistics from four sets of published results were used 
to identify health problems among patients treated for acute lymphoblastic leukemia 
in childhood in a recently published study. Results from the Joint Canada/US Survey of 
Health (JCUSH), conducted at the same time in both countries using the same survey 
methodology are presented here in brief. The mean HUI3 score in Canada (0.88) was 
slightly higher than in the US (0.87) (p< 0.05). However, the mean HUI3 score for those 
with less than a high school education in Canada (0.81) was much higher than the 
mean for the same group in the US (0.74) (p< 0.05). HUI Mark2 (HUI2) and HUI Mark3 
(HUI3) summary statistics by country, gender, race and age groups are presented in 
43 tables on the HUI web-site (www.healthutilities.com). ConClusions: The results 
highlight the usefulness of continuous preference-based measures of population 
health such as the HUI3. Population reference data enable international comparisons 
of population health and provide normative data with which to interpret results from 
clinical studies. The publicly available summary statistics of interval-scale preference-
based measures for the HRQL of reference populations provide valid, reliable and 
cost-effective results for clinical and general population studies.
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level dynamic Bayesian inhomogeneous Markov model with quarterly time-step 
was then developed to jointly describe prescriptions and outcomes over time 
in relation with adherence proxy using medication possession ratio, adjusting 
for patients demographics and seasonality. Internal and external validation was 
performed. Results: . Such Bayesian model could be fitted to the available data 
with different parameters informed by one or another data source. Treatment 
switches were associated with severity at the previous quarter while adherence 
was significantly improved when patients are switched and when they are less 
controlled in the previous quarter. Risk of exacerbations was depending on the 
control score and season at the present quarter and on the risk of exacerbation 
at the previous quarter. Control was significantly improved by a better adherence 
and to a lesser extent by a treatment escalation and improved severity at the previ-
ous quarter. ConClusions: This Bayesian dynamic model allowed quantifying 
the most important interactions between drug uses and effects on control and 
exacerbations over time, hence providing a powerful tool for real-world outcomes 
predictions in asthma patients.
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objeCtives: Large scale simulation models (e.g. Archimedes Model, MISCAN) are 
increasingly used to predict cost-effectiveness of medical interventions and to 
drive reimbursement decisions. These models are complex and involve hundreds 
of parameters and inputs. Quantification of parameter uncertainties using tradi-
tional sampling-based approaches (e.g., Monte Carlo sampling and its variants) can 
be prohibitively expensive for these models. Methods: We overcome the limita-
tions of traditional probabilistic sensitivity analysis through a 4-step process. First, 
we conduct a thorough survey of all parameters and their confidence intervals. 
Second, we use local sensitivity analysis to evaluate the effects of each parameter 
on the outcome of interest. Third, based on results from single-parameter sensitivity 
analysis, we rank and identify a group of parameters that have the largest effects 
on the outcome. We then employ response surface (RS) approximation methods 
to create a mathematical model of the model predictions for these parameters. 
We use Latin Hypercube sampling (LHS) to generate data points and multivariate 
adaptive regression splines (MARS) to build the response surface approximations. 
Fourth, we sample parameters from their joint distributions, and then use the con-
structed response surface to calculate the probability distribution of the predicted 
outcomes. Results: We apply the above methodology to quantify uncertainties 
in predictions of the Archimedes Model for effectiveness of colorectal cancer (CRC) 
screening by colonoscopy (COLO) and fecal immunological test (FIT). We started out 
with 200 parameters and identified 20 parameters that have significant influences 
on predicted effectiveness of CRC screening. We conclude that there is a 89% chance 
that COLO will save more life years FIT, after accounting for parameter uncertainties. 
Similarly we estimate that there is a 61% probability that FIT is more cost effective 
than colonoscopy. ConClusions: We have developed a robust and efficient meth-
odology for quantifying parameter uncertainties of large-scale simulation models 
used for cost-effectiveness analysis.
ReseaRCh on MethoDs – Patient-Reported outcomes studies
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objeCtives: EQ-5D catalogues have been developed and tested in US and UK. The 
current study aims to develop a Danish preference-based EQ-5D 3L scores cata-
logue for around a hundred of the most common monitored chronic conditions. The 
development is based on experiences from the US and UK, but adding new factors of 
importance such as health habits, BMI, social networks and stress. Methods: The 
marginal disutility estimates will be calculated using CLAD and OLS regression on a 
single source population from a random sample: the National Danish Health Survey 
Data from 2010 which is a self-administrated survey with approx. 38.000 respond-
ents age ≥ 16. The survey data is combined with data from national registers contain-
ing individual health data e.g. diagnosed chronic conditions during hospitalization, 
medication, use of hospitals as well as socio-economic data. The catalogue differs 
from UK and US catalogues’ by adding health habits information and by using ICD-
10 classifications from registers as well as it is based on Danish EQ-5D tariffs. The 
marginal disutility is calculated for each chronic condition controlling for age, gen-
der, ethnicity, income, education and comorbidity etc. Results: Marginal disutility 
estimates (EQ-5D) for around a hundred ICD-10 chronic conditions are presented 
and compared. It is expected that this new knowledge will contribute and qualify 
prioritization debate, when results are published and combined with knowledge of 
for example factors of importance and burden of disease in costs. ConClusions: 
The catalogue will provide scientist with an “off-the-shelf” tool for use in health eco-
nomic evaluations. Marginal disutilities estimates can be used to estimate QALY’s 
in CEA for a wide variety of conditions in Denmark.
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objeCtives: Phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of erec-
tile dysfunction (ED) have similar pharmacologic profile. Patient preferences may 
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for use in diabetes (n = 11; 13%) ), then 7 pain instruments (8%), 5 respiratory question-
naires (6%), 2 urological questionnaires (2%) and 2 treatment specific instruments 
(2%). The remaining 30 (34%) instruments covered individual conditions ranging from 
anaemia to osteoporosis. ConClusions: There are at least 88 patient’s treatment 
satisfaction/preference instruments published for possible use in clinical trials; 31 of 
which are useful for evaluating satisfaction / preference for drug therapies without 
reference to a specific therapy area. For those disease-specific measures, assessment 
of content validity and psychometric properties should be assessed before chosing 
the most appropriate measure for a given study.
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objeCtives: To determine whether dual back-translators improve the transla-
tion process for Patient Report Outcomes (PRO). Methods: Four (4) PROs were 
translated using dual back-translators. The two back-translators worked indepen-
dently, possessing no knowledge of the other’s back-translation. The translated PROs 
were: a physical assessment questionnaire containing 1507 words with medical 
terminology, a physical assessment questionnaire with simple terminology con-
taining 593 words, a COPD questionnaire containing medical concepts with 713 
words, and a cancer treatment questionnaire containing colloquial terminology 
and 403 words. Instances of the following scenario were tallied during analysis: 
one back-translation accurately reflected the source, the other back-translation 
inaccurately reflected the source, but revealed an error in the forward translation. 
The same PROs were analyzed again, focusing only on one of the back-translators 
to compare the number of forward translation revisions that occur when using a 
single back-translator. Results: After analysis, 184 forward translation revisions 
occurred when using dual back-translators. 11 out of the 184 were a revision to a 
forward translation where one back-translation was correct despite the other back-
translation being incorrect. This occurred 4 times amongst Slavic family languages, 
3 times amongst Indian languages, 3 times amongst Southeast Asian languages, and 
once with Chinese. No such revisions occurred amongst Latin and Germanic lan-
guage families. After analysis of the translated PROs with just one back-translator, 
a total of 180 forward translation revisions occurred. ConClusions: A second 
back-translation improves the translation process if the readability of the text of 
higher difficulty, and if Slavic, Asian and Indian language translations are required. 
However, the low number of revisions resulting from one incorrect back-transla-
tion, while using dual back-translators, demonstrates that one back-translator is 
acceptable. Since dual back-translators revealed the need for only 4 more forward 
translation revisions than the single back-translator, the quality output is similar.
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objeCtives: To demonstrate the increased use of mobile phones to collect patient 
reported outcomes in research and to show that they are a valid method of data col-
lection. Methods: A literature search was conducted looking at articles published 
between 2009 and 2013 that referenced electronic diaries of some description. Articles 
were pulled out that specifically referenced mobile or cellular phones. Results: 
Twenty-four of out of 157 articles found specifically referenced mobile. The studies 
referenced in these articles were carried out on populations with an age range of 8 
years up to 70 and were split into 12 therapy areas including metabolic and genetic 
disorders, pain, weight management, sexual activity, respiratory and alcohol related. 
Population size ranged from 15 to 994 (mean 145.6; SD-180), and subjects reported 
for a minimum of 7 days (up to 6 reports per day) to a maximum of 365 days (mean 
107.9 days; SD-112.6). Notably, 17 out of the 24 studies allowed the subjects to use 
their own mobile phone for the reporting and 11 referenced smartphones specifi-
cally. ConClusions: All concluded that mobile phones were suited to collect data 
from subjects. It was noted that the use of mobiles was acceptable as they are used 
them in everyday life and found to be convenient; the technology was also inexpen-
sive to implement. The fact that 70.8% of the studies allowed the subjects to use their 
own mobile phones for the reporting emphasises the practicality of using mobile 
phones in patient reported outcomes. Although the mean age of all the studies was 
relatively low, the age range was very wide and researchers can be confident that 
older populations could use mobile phones to collect these data. The rapid adoption 
and technical evolution of mobile technologies and ubiquitous nature show that this 
technology is a valid means to collect patient reported outcomes.
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objeCtives: The lack of empirical and well-accepted cost-effectiveness (CE) thresh-
old is recognized as one of the most important barriers in using Health technology 
assessment (HTA) in policy decisions and this is no exception in Asia Pacific region. 
HTAsiaLink, a network of HTA organizations in Asia has embarked on first collabora-
tive research on determining the CE threshold across 4 countries in Asia Pacific region 
namely Korea, Japan, Malaysia, and Thailand. This pilot study aimed 1)to explore 
the feasibility of the instrument/methods used 2)to examine the value of a quality-
adjusted life-year (QALY) associated with improving quality of life in mild, moderate 
and severe health condition, and extending life during terminal illness. Methods: 
Five EQ-5D health states with different health severity (11121, 11212, 11323, 11223 
objeCtives: There is a variety of disease modifying drugs available for the 
treatment of multiple sclerosis (MS). These drugs are associated with different 
characteristics in key attributes such as side effects, mode of administration etc. 
The current study was carried out to assess the importance of treatment charac-
teristics for patients’ preferences in an ecologically valid design. Methods: In 
a discrete choice experiment (DCE), MS patients from 38 neurological practices 
in Germany (n= 1,153) were asked to choose the most and the least preferred 
drug (best-worst-scaling) among hypothetical multi-attribute alternatives with 
varying levels of the following key attributes: mode of administration, local and 
systemic side effects, frequency of administration, and required monitoring of the 
patient. This design (Case-3, multi-profile case) simulates a real choice situation 
between different hypothetical multi-attribute pharmaceutical treatment alterna-
tives. Results: On average, patients (~75% female) were 42 years of age with 9.6 
years of disease duration, and ~90% reporting prior experience with parenteral 
modes of administration. Count analysis (Flynn & Louviere, 1992; Orme, 2009) 
yielded that mode of administration was the most important attribute guiding 
patients’ preferences, with ‘oral application’ being most desired (selected as best 
option in 63% of the cases). Notably, the studied systemic side effects, such as 
flu-like symptoms or gastrointestinal disorders were only half as important as 
mode of administration for patients’ choice. The second most relevant attribute 
was frequency of administration, with ‘administration once a week’ being the most 
preferred attribute level (in 47% of the cases). ConClusions: Our data indicate 
that for MS patients, the most important attributes of MS disease modifying drugs 
are route of administration (oral being the number one choice by majority) and 
frequency of administration (with intake once a week being the most preferred), 
probably because these aspects meet the patients’ need for low treatment burden 
in daily life.
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objeCtives: Work-loss disability from ailments especially depression become 
shortcoming in economic development thus demands early reverts. No reliable tool 
to evaluate work-loss diability in Thai developed. We assessed reliability and validity 
of Thai version of Lam Employment Absence and Productivity Scale (LEAPS),direct 
patient report outcome subsequent to ailments. Methods: An original LEAPS 
was officially acquired,validated by language experts, distributed to field-test 
from patients age above 18 years with ailments seeking treatment at hospital. The 
scale reliability employed item-scale and inter-item consistency with standardized 
Chronbach’s alpha coefficient. The scale discrimination for patient with income or 
non-income job was determined and compared using area under curve for Receiver 
Operating Characteristics (AuROC) with Chi-square test. Results: There were 
seven main LEAPS items with five responder choices. Of 201 patients, 86(42.8%) 
male,115(57.2%) female, mean (SD)age of 39.6(15.2) years recruited from 3 hospitals. 
132(65.7%) and 69(34.3%) patients were classed in income job and non-income job 
respectively. Background education were graduate 76(38%), vocational certificate 
35(17.5%), high school 42 (21%) and primary education 42(21%). 74 (37.2%) of patients 
had been diagnosed with co-morbidities whom 13(18%) and 61(82%) were psycho-
logical and physical illness respectively. Overall 120(60%) of patients complained 
about their health problems which demanded medical treatment within one week, 
where 58(29%) reported the condition not interfere with daily activities whereas 
36(18%) indicated that the conditions were severe and needed hospitalization. 
The responder to LEAPS was 94.5%. Reliability test for overall internal consistency 
Chronbach’s alpha coefficient were 0.834 with AuROC of 0.78,95%CI:0.72-0.85. The 
AuROC for non-income generating vs income-generating group of 0.82,95%CI:0.71-
0.92 vs 0.77,95%CI:0.69-0.86 were not significant different (p= 0.528) with correspond-
ing Chronbach’s alpha coefficient of 0.811 vs 0.842 (p= 0.667). ConClusions: Thai 
version Lam Employment Absence and Productivity Scale(LEAPS) is reliable to use 
among Thai patients. The scale is robust with consistency among Thai patients with 
employment and loss productivity regardless of income-generating job and highly 
predictive for work-loss disability.
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objeCtives: To determine the availability of Patient Reported Outcome (PRO) 
instruments measuring Patient’s Treatment Satisfaction and/or Preference for drug 
therapies. Methods: The authors conducted a systematic review of the published 
literature using established biomedical literature databases (Medline and Embase), 
ClinicalTrials.gov as well as a PRO specific database (PROQOLID). The instruments 
identified through the various sources were selected according to specific criteria: 1) 
Include: PRO instruments of Treatment Satisfaction or Preference as a sole concept OR 
PRO instruments with at least two domains of Treatment Satisfaction or Preference; 2) 
Exclude: Evaluation of biomarker control OR No information found on the PRO instru-
ments. Results: The systematic literature review identified a total of 720 articles on 
biomedical databases and 1634 closed clinical trials on Clinicaltrials.gov. The search 
in PROQOLID identified ten PRO instruments. From an initial review, 130 instruments 
were considered of particular relevance. Upon detailed review, 88 PRO instruments 
met selection criteria - nine of which were solely designed for a specific study. Of these 
88 PRO instruments, 31 were generic (35%). The most disease-specific measures were 
